Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 + midostaurin + CD34+ selected allogeneic stem cell transplant
- Development stage
- Unknown
- Lead developer
- Miami Cancer Institute
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This treatment protocol is a multi-component regimen designed for patients with high-risk FLT3-mutated acute myeloid leukemia (AML). It integrates induction and consolidation therapy using CPX-351 (a liposomal combination of daunorubicin and cytarabine) and midostaurin (a FLT3 inhibitor) to achieve remission. Following this, patients undergo a conditioning regimen consisting of busulfan, melphalan, and fludarabine, followed by a CD34+ selected allogeneic stem cell transplant. The CD34+ selection process involves the enrichment of hematopoietic stem cells and the depletion of T-cells from the donor graft, a technique intended to minimize the risk of graft-versus-host disease (GVHD) while maintaining the graft-versus-leukemia effect. This specific pilot study is led by Guenther Koehne.
- Other names
- CD34+ selected allogeneic stem cell transplant-Guenther Koehne-acute myeloid leukemiaCPX-351 and Midostaurin for FLT3 Mutated AMLCPX351 and Midostaurin for FLT3 Mutated AMLCPX 351 and Midostaurin for FLT3 Mutated AML
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)TOP2A (DNA topoisomerase II)DNASFK (SRC family kinases)DNA polymerase familyFLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on CPX-351 + midostaurin + CD34+ selected allogeneic stem cell transplant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 + midostaurin + CD34+ selected allogeneic stem cell transplant.